Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Fanale

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2015
Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed diseaseAmer Beitinjaneh, Rima M Saliba, L Jeffrey Medeiros, et al.
Journal of Hematology & Oncology|March 20, 2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesNancy L Bartlett, Robert Chen, Michelle A Fanale, et al.
Haematologica|September 8, 2018
ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 studyPaolo Strati, Michelle A Fanale, Yasuhiro Oki, et al.
International Journal of Radiation Oncology, Biology, Physics|June 22, 2016
Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With RadiationJillian R Gunther, Michelle A Fanale, Jay P Reddy, et al.
Cancer|December 17, 2016
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantationSarah A Milgrom, Shekeab Jauhari, John P Plastaras, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
British Journal of Haematology|July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky diseaseFelipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.
Leukemia & Lymphoma|August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignanciesAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Haematologica|May 11, 2019
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasPaolo Strati, Loretta J Nastoupil, Richard E Davis, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2015
Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed diseaseAmer Beitinjaneh, Rima M Saliba, L Jeffrey Medeiros, et al.
Journal of Hematology & Oncology|March 20, 2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignanciesNancy L Bartlett, Robert Chen, Michelle A Fanale, et al.
Haematologica|September 8, 2018
ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 studyPaolo Strati, Michelle A Fanale, Yasuhiro Oki, et al.
International Journal of Radiation Oncology, Biology, Physics|June 22, 2016
Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With RadiationJillian R Gunther, Michelle A Fanale, Jay P Reddy, et al.
Cancer|December 17, 2016
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantationSarah A Milgrom, Shekeab Jauhari, John P Plastaras, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
British Journal of Haematology|July 22, 2014
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky diseaseFelipe Samaniego, Zuzana Berkova, Jorge E Romaguera, et al.
Leukemia & Lymphoma|August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignanciesAndres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Haematologica|May 11, 2019
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomasPaolo Strati, Loretta J Nastoupil, Richard E Davis, et al.
Pageof 9